The United Kingdom and the United States have reached a key trade agreement that will maintain no duties on British pharmaceutical shipments being sold in the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise expenditure on drugs through the public health system. This pledge secures that duties on these vital goods will remain at nothing for a period of three years.
This deal is in response to earlier warnings to dramatically increase duties on branded pharmaceutical products, with potential rates floated as high as 100%.
"This arrangement with the Britain reinforces the global environment for new treatments and introduces much-needed equity to transatlantic pharmaceutical trade," an announcement said.
Commercial Importance
Medicines constitute one of the UK's most significant exports to the United States, which is easily the largest market for leading UK drugmakers.
Export figures reveal that in the one-year period to the end of the third quarter, the UK sold drugs valued at over eleven billion pounds to the US. This figure accounted for a significant portion of total UK exports in that period.
"This deal secures work, stimulates investment and sets the stage for the UK to establish itself as a global hub for life sciences," a government official remarked.
Specific NHS Changes
The agreement entails several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to raise overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates topped twenty percent.
Recent Tensions
The deal comes amid a long-running tension between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
These tensions were intensified by arguments that American patients were charged a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
